ELAN vs. LEGN, VKTX, ROIV, CERE, ASND, JAZZ, ITCI, CTLT, BPMC, and CYTK
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include Legend Biotech (LEGN), Viking Therapeutics (VKTX), Roivant Sciences (ROIV), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Intra-Cellular Therapies (ITCI), Catalent (CTLT), Blueprint Medicines (BPMC), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical preparations" industry.
Legend Biotech (NASDAQ:LEGN) and Elanco Animal Health (NYSE:ELAN) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, community ranking, risk, institutional ownership and earnings.
70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 0.6% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Legend Biotech had 19 more articles in the media than Elanco Animal Health. MarketBeat recorded 30 mentions for Legend Biotech and 11 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.55 beat Legend Biotech's score of 0.06 indicating that Legend Biotech is being referred to more favorably in the media.
Legend Biotech currently has a consensus target price of $82.74, indicating a potential upside of 83.21%. Elanco Animal Health has a consensus target price of $18.29, indicating a potential upside of 6.31%. Given Elanco Animal Health's stronger consensus rating and higher probable upside, research analysts clearly believe Legend Biotech is more favorable than Elanco Animal Health.
Legend Biotech has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.
Elanco Animal Health has a net margin of -29.83% compared to Elanco Animal Health's net margin of -135.92%. Legend Biotech's return on equity of 5.98% beat Elanco Animal Health's return on equity.
Legend Biotech has higher earnings, but lower revenue than Elanco Animal Health. Legend Biotech is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Elanco Animal Health received 72 more outperform votes than Legend Biotech when rated by MarketBeat users. However, 64.13% of users gave Legend Biotech an outperform vote while only 54.13% of users gave Elanco Animal Health an outperform vote.
Summary
Legend Biotech and Elanco Animal Health tied by winning 9 of the 18 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
